Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma.

Karkhanis V, Alinari L, Ozer HG, Chung J, Zhang X, Sif S, Baiocchi RA.

J Biol Chem. 2019 Dec 10. pii: jbc.RA119.008742. doi: 10.1074/jbc.RA119.008742. [Epub ahead of print]

2.

Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.

Bond DA, Alinari L, Maddocks K.

Clin Adv Hematol Oncol. 2019 Apr;17(4):223-233. Review.

PMID:
31188814
3.

Modulation of immune checkpoint molecule expression in mantle cell lymphoma.

Harrington BK, Wheeler E, Hornbuckle K, Shana'ah AY, Youssef Y, Smith L, Hassan Ii Q, Klamer B, Zhang X, Long M, Baiocchi RA, Maddocks K, Johnson AJ, Byrd JC, Alinari L.

Leuk Lymphoma. 2019 Oct;60(10):2498-2507. doi: 10.1080/10428194.2019.1569231. Epub 2019 Mar 1.

4.

PLK1: a promising and previously unexplored target in double-hit lymphoma.

Hassan QN 2nd, Alinari L, Byrd JC.

J Clin Invest. 2018 Dec 3;128(12):5206-5208. doi: 10.1172/JCI124919. Epub 2018 Nov 5.

5.

Awakening exhausted NK cells in lymphomas.

Alinari L.

Blood. 2018 Apr 19;131(16):1768-1769. doi: 10.1182/blood-2018-03-835173. No abstract available.

PMID:
29674350
6.

Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.

Shindiapina P, Alinari L.

Ther Adv Hematol. 2018 Apr;9(4):89-105. doi: 10.1177/2040620718761777. Epub 2018 Mar 5. Review.

7.

BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.

Ozer HG, El-Gamal D, Powell B, Hing ZA, Blachly JS, Harrington B, Mitchell S, Grieselhuber NR, Williams K, Lai TH, Alinari L, Baiocchi RA, Brinton L, Baskin E, Cannon M, Beaver L, Goettl VM, Lucas DM, Woyach JA, Sampath D, Lehman AM, Yu L, Zhang J, Ma Y, Zhang Y, Spevak W, Shi S, Severson P, Shellooe R, Carias H, Tsang G, Dong K, Ewing T, Marimuthu A, Tantoy C, Walters J, Sanftner L, Rezaei H, Nespi M, Matusow B, Habets G, Ibrahim P, Zhang C, Mathé EA, Bollag G, Byrd JC, Lapalombella R.

Cancer Discov. 2018 Apr;8(4):458-477. doi: 10.1158/2159-8290.CD-17-0902. Epub 2018 Jan 31.

8.

Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.

Bond DA, Alinari L.

J Blood Med. 2017 May 11;8:41-54. doi: 10.2147/JBM.S117452. eCollection 2017. Review.

9.

Toward autophagy-targeted therapy in lymphoma.

Alinari L.

Blood. 2017 Mar 30;129(13):1740-1742. doi: 10.1182/blood-2017-02-764639. No abstract available.

PMID:
28360356
10.

Pembrolizumab in classical Hodgkin's lymphoma.

Maly J, Alinari L.

Eur J Haematol. 2016 Sep;97(3):219-27. doi: 10.1111/ejh.12770. Epub 2016 May 30. Review.

11.

De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.

Alinari L, Gru A, Quinion C, Huang Y, Lozanski A, Lozanski G, Poston J, Venkataraman G, Oak E, Kreisel F, Park SI, Matthews S, Abramson JS, Iris Lim H, Martin P, Cohen JB, Evens A, Al-Mansour Z, Singavi A, Fenske TS, Blum KA.

Am J Hematol. 2016 Jun;91(4):395-9. doi: 10.1002/ajh.24299.

12.

How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant.

Alinari L, Blum KA.

Blood. 2016 Jan 21;127(3):287-95. doi: 10.1182/blood-2015-10-671826. Epub 2015 Nov 17. Review.

PMID:
26576863
13.

The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation.

Tarighat SS, Santhanam R, Frankhouser D, Radomska HS, Lai H, Anghelina M, Wang H, Huang X, Alinari L, Walker A, Caligiuri MA, Croce CM, Li L, Garzon R, Li C, Baiocchi RA, Marcucci G.

Leukemia. 2016 Apr;30(4):789-99. doi: 10.1038/leu.2015.308. Epub 2015 Nov 5.

PMID:
26536822
14.

Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.

Alinari L, Mahasenan KV, Yan F, Karkhanis V, Chung JH, Smith EM, Quinion C, Smith PL, Kim L, Patton JT, Lapalombella R, Yu B, Wu Y, Roy S, De Leo A, Pileri S, Agostinelli C, Ayers L, Bradner JE, Chen-Kiang S, Elemento O, Motiwala T, Majumder S, Byrd JC, Jacob S, Sif S, Li C, Baiocchi RA.

Blood. 2015 Apr 16;125(16):2530-43. doi: 10.1182/blood-2014-12-619783. Epub 2015 Mar 5.

15.

Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas.

Alinari L, Quinion C, Blum KA.

Clin Pharmacol Ther. 2015 May;97(5):469-77. doi: 10.1002/cpt.65. Epub 2015 Jan 20. Review.

PMID:
25670208
16.

Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.

Yan F, Alinari L, Lustberg ME, Martin LK, Cordero-Nieves HM, Banasavadi-Siddegowda Y, Virk S, Barnholtz-Sloan J, Bell EH, Wojton J, Jacob NK, Chakravarti A, Nowicki MO, Wu X, Lapalombella R, Datta J, Yu B, Gordon K, Haseley A, Patton JT, Smith PL, Ryu J, Zhang X, Mo X, Marcucci G, Nuovo G, Kwon CH, Byrd JC, Chiocca EA, Li C, Sif S, Jacob S, Lawler S, Kaur B, Baiocchi RA.

Cancer Res. 2014 Mar 15;74(6):1752-65. doi: 10.1158/0008-5472.CAN-13-0884. Epub 2014 Jan 22.

17.

Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.

Alinari L, Prince CJ, Edwards RB, Towns WH, Mani R, Lehman A, Zhang X, Jarjoura D, Pan L, Kinghorn AD, Grever MR, Baiocchi RA, Lucas DM.

Clin Cancer Res. 2012 Sep 1;18(17):4600-11. doi: 10.1158/1078-0432.CCR-12-0839. Epub 2012 Jul 12.

18.

Lymphomatoid granulomatosis presenting with gingival involvement in an immune competent elderly male.

Alinari L, Pant S, McNamara K, Kalmar JR, Marsh W, Allen CM, Baiocchi RA.

Head Neck Pathol. 2012 Dec;6(4):496-501. doi: 10.1007/s12105-012-0378-z. Epub 2012 Jun 19.

19.
20.

Novel targeted therapies for mantle cell lymphoma.

Alinari L, Christian B, Baiocchi RA.

Oncotarget. 2012 Feb;3(2):203-11.

21.

FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.

Alinari L, Mahoney E, Patton J, Zhang X, Huynh L, Earl CT, Mani R, Mao Y, Yu B, Quinion C, Towns WH, Chen CS, Goldenberg DM, Blum KA, Byrd JC, Muthusamy N, Praetorius-Ibba M, Baiocchi RA.

Blood. 2011 Dec 22;118(26):6893-903. doi: 10.1182/blood-2011-06-363879. Epub 2011 Oct 31.

22.

Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.

Baiocchi RA, Alinari L, Lustberg ME, Lin TS, Porcu P, Li X, Johnston JS, Byrd JC, Blum KA.

Cancer. 2011 Jun 1;117(11):2442-51. doi: 10.1002/cncr.25792. Epub 2010 Dec 14.

23.

Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.

Alinari L, Yu B, Christian BA, Yan F, Shin J, Lapalombella R, Hertlein E, Lustberg ME, Quinion C, Zhang X, Lozanski G, Muthusamy N, Prætorius-Ibba M, O'Connor OA, Goldenberg DM, Byrd JC, Blum KA, Baiocchi RA.

Blood. 2011 Apr 28;117(17):4530-41. doi: 10.1182/blood-2010-08-303354. Epub 2011 Jan 12.

24.

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.

Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC.

Blood. 2010 Nov 11;116(19):3705-14. doi: 10.1182/blood-2010-04-001230. Epub 2010 Jul 7. Review.

25.

The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo.

Lucas DM, Alinari L, West DA, Davis ME, Edwards RB, Johnson AJ, Blum KA, Hofmeister CC, Freitas MA, Parthun MR, Wang D, Lehman A, Zhang X, Jarjoura D, Kulp SK, Croce CM, Grever MR, Chen CS, Baiocchi RA, Byrd JC.

PLoS One. 2010 Jun 3;5(6):e10941. doi: 10.1371/journal.pone.0010941.

26.

FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma.

Liu Q, Alinari L, Chen CS, Yan F, Dalton JT, Lapalombella R, Zhang X, Mani R, Lin T, Byrd JC, Baiocchi RA, Muthusamy N.

Clin Cancer Res. 2010 Jun 15;16(12):3182-92. doi: 10.1158/1078-0432.CCR-09-2484. Epub 2010 May 11.

27.

New targets of therapy in T-cell lymphomas.

Erter J, Alinari L, Darabi K, Gurcan M, Garzon R, Marcucci G, Bechtel MA, Wong H, Porcu P.

Curr Drug Targets. 2010 Apr;11(4):482-93. Review.

28.

Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.

Alinari L, White VL, Earl CT, Ryan TP, Johnston JS, Dalton JT, Ferketich AK, Lai R, Lucas DM, Porcu P, Blum KA, Byrd JC, Baiocchi RA.

MAbs. 2009 Jan-Feb;1(1):31-40.

29.

Methylation of histone H3 and H4 by PRMT5 regulates ribosomal RNA gene transcription.

Majumder S, Alinari L, Roy S, Miller T, Datta J, Sif S, Baiocchi R, Jacob ST.

J Cell Biochem. 2010 Feb 15;109(3):553-63. doi: 10.1002/jcb.22432.

30.

Enhancement of TRAIL cytotoxicity by AG-490 in human ALL cells is characterized by downregulation of cIAP-1 and cIAP-2 through inhibition of Jak2/Stat3.

Lanuti P, Bertagnolo V, Pierdomenico L, Bascelli A, Santavenere E, Alinari L, Capitani S, Miscia S, Marchisio M.

Cell Res. 2009 Sep;19(9):1079-89. doi: 10.1038/cr.2009.80. Epub 2009 Jun 30.

PMID:
19564891
31.

Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma.

Zinzani PL, Stefoni V, Tani M, Fanti S, Musuraca G, Castellucci P, Marchi E, Fina M, Ambrosini V, Pellegrini C, Alinari L, Derenzini E, Montini G, Broccoli A, Bacci F, Pileri S, Baccarani M.

J Clin Oncol. 2009 Apr 10;27(11):1781-7. doi: 10.1200/JCO.2008.16.1513. Epub 2009 Mar 9.

PMID:
19273712
32.

Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.

Derenzini E, Musuraca G, Fanti S, Stefoni V, Tani M, Alinari L, Venturini F, Gandolfi L, Baccarani M, Zinzani PL.

Cancer. 2008 Nov 1;113(9):2496-503. doi: 10.1002/cncr.23861.

33.

A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.

Zinzani PL, Tani M, Fanti S, Stefoni V, Musuraca G, Castellucci P, Marchi E, Farsad M, Fina M, Pellegrini C, Alinari L, Derenzini E, de Vivo A, Bacci F, Pileri S, Baccarani M.

Ann Oncol. 2008 Apr;19(4):769-73. doi: 10.1093/annonc/mdm560. Epub 2008 Feb 25.

34.

Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly.

Alinari L, Geskin L, Grady T, Baiocchi RA, Bechtel MA, Porcu P.

Leuk Res. 2008 Aug;32(8):1299-303. Epub 2007 Dec 21.

PMID:
18096224
35.

VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly.

Fina M, Tani M, Stefoni V, Musuraca G, Marchi E, Pellegrini C, Alinari L, Derenzini E, Bacci F, Pileri S, Baccarani M, Zinzani PL.

Leuk Lymphoma. 2007 Nov;48(11):2167-71.

PMID:
17990178
36.

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.

Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M, Pellegrini C, Alinari L, Derenzini E, de Vivo A, Sabattini E, Pileri S, Baccarani M.

J Clin Oncol. 2007 Sep 20;25(27):4293-7. Epub 2007 Aug 20.

PMID:
17709797
37.

Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma.

Zinzani PL, Tani M, Trisolini R, Fanti S, Stefoni V, Alifano M, Castellucci P, Musuraca G, Dalpiaz G, Alinari L, Marchi E, Fina M, Pellegrini C, Farsad M, Cancellieri A, Busca A, Canini R, Pileri S, Baccarani M, Boaron M.

Haematologica. 2007 Jun;92(6):771-7.

38.

Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.

Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC.

Oncogene. 2007 May 28;26(25):3644-53. Review.

PMID:
17530018
39.

Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma.

Zinzani PL, Musuraca G, Alinari L, Fanti S, Tani M, Stefoni V, Marchi E, Fina M, Pellegrini C, Castellucci P, Farsad M, Baccarani M.

Clin Lymphoma Myeloma. 2007 Jan;7(4):291-5.

PMID:
17324337
40.

18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma.

Alinari L, Castellucci P, Elstrom R, Ambrosini V, Stefoni V, Nanni C, Berkowitz A, Tani M, Farsad M, Franchi R, Fanti S, Zinzani PL.

Leuk Lymphoma. 2006 Oct;47(10):2096-101.

PMID:
17071482
41.

Discordant response to chemotherapy: an unusual pattern of fluoro-deoxy-D-glucose uptake in heavily pre-treated lymphoma patients.

Alinari L, Ambrosini V, Castellucci P, Tani M, Stefoni V, Nanni C, Farsad M, Rubello D, Franchi R, Zinzani PL, Fanti S.

Leuk Lymphoma. 2006 Jun;47(6):1048-52.

PMID:
16840196
42.

Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients.

Zinzani PL, Tani M, Fanti S, Alinari L, Musuraca G, Marchi E, Stefoni V, Castellucci P, Fina M, Farshad M, Pileri S, Baccarani M.

Ann Oncol. 2006 Aug;17(8):1296-300. Epub 2006 Jun 9.

PMID:
16766583
43.

Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas.

Zinzani PL, Quaglino P, Pimpinelli N, Berti E, Baliva G, Rupoli S, Martelli M, Alaibac M, Borroni G, Chimenti S, Alterini R, Alinari L, Fierro MT, Cappello N, Pileri A, Soligo D, Paulli M, Pileri S, Santucci M, Bernengo MG; Italian Study Group for Cutaneous Lymphomas.

J Clin Oncol. 2006 Mar 20;24(9):1376-82. Epub 2006 Feb 21.

PMID:
16492713
44.

Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas.

Stefoni V, Alinari L, Musuraca G, Tani M, Marchi E, Gabriele A, Fina M, Pileri S, Baccarani M, Zinzani PL.

Leuk Lymphoma. 2005 Dec;46(12):1839-41. No abstract available.

PMID:
16263591
45.

Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma.

Alinari L, Musuraca G, Tani M, Stefoni V, Gabriele A, Marchi E, Fina M, De Vivo A, Pileri S, Baccarani M, Zinzani PL.

Leuk Lymphoma. 2005 Oct;46(10):1437-40.

PMID:
16252433
46.

Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients.

Marchi E, Alinari L, Tani M, Stefoni V, Pimpinelli N, Berti E, Pagano L, Bernengo MG, Zaja F, Rupoli S, Pileri S, Baccarani M, Zinzani PL.

Cancer. 2005 Dec 1;104(11):2437-41.

47.

Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy.

Zinzani PL, Tani M, Alinari L, Molinari AL, Stefoni V, Visani G, Gentilini P, Guardigni L, Fina M, Baccarani M.

Leuk Lymphoma. 2005 Oct;46(10):1449-54.

PMID:
16194890
48.

Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma.

Tani M, Fina M, Alinari L, Stefoni V, Baccarani M, Zinzani PL.

Haematologica. 2005 Sep;90(9):1283-4.

49.

Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation.

Castellucci P, Nanni C, Farsad M, Alinari L, Zinzani P, Stefoni V, Battista G, Valentini D, Pettinato C, Marengo M, Boschi S, Canini R, Baccarani M, Monetti N, Franchi R, Rampin L, Fanti S, Rubello D.

Nucl Med Commun. 2005 Aug;26(8):689-94.

PMID:
16000986
50.

Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma.

Zinzani PL, Alinari L, Tani M, Fina M, Pileri S, Baccarani M.

Haematologica. 2005 May;90(5):702-3.

Supplemental Content

Loading ...
Support Center